



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Veldhuis et al.

Serial No.: 10/676,847

Filed: October 1, 2003

For: METHOD OF TREATMENT OF
HYPOXIA/ISCHAEMIA

Confirmation No.: Unknown

Examiner: To be assigned

Group Art Unit: To be assigned

Attorney Docket No.: 2183-6139US

CERTIFICATE OF MAILING

I hereby certify that this correspondence along with any attachments referred to or identified as being attached or enclosed is being deposited with the United States Postal Service as First Class Mail on the date of deposit shown below with sufficient postage and in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

December 1, 2003
Date

Bonnie L. Huntsman
Signature

Bonnie L. Huntsman
Name (Type/Print)

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In compliance with the duty to disclose information material to patentability pursuant to 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the document listed on attached Form PTO-1449 or PTO/SB/08 be considered by the Examiner and made of record. A copy of the listed document is enclosed pursuant to 37 C.F.R. § 1.98(a).

In accordance with 37 C.F.R. § 1.97(g) and (h), filing of this Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made or an admission that the information cited herein is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b). Further, no representation is made by Applicants herein that no other possible material information as defined in 37 C.F.R. § 1.56 (b) exists.

Serial No. «Patent Application No»

Other Documents

LIU et al., Interferon-B administration confers a beneficial outcome in a rabbit model of thromboembolic cerebral ischemia, Neuroscience Letters, 2002, pp. 146-48, Vol. 327.

In compliance with the duty to disclose information material to patentability pursuant to 37 C.F.R. § 1.56, Applicants hereby identify the following listed copending applications naming a common inventor:

Attorney Docket No.: 2183-6141US
Serial No.: 10/678,957
Filing Date: 10/3/2003
Title: AT LEAST PARTIAL PREVENTION AND/OR REDUCTION OF
CELLULAR DAMAGE IN TISSUE THAT HAS SUFFERED
FROM OR IS SUFFERING FROM HYPOXIA AND/OR
ISCHAEMIA AND/OR INFLAMMATION

This Supplemental Information Disclosure Statement is filed within three (3) months of the filing date of the above-identified application.

Respectfully submitted,



Allen C. Turner
Registration No. 33,041
Attorney for Applicant(s)
TRASKBRITT
P.O. Box 2550
Salt Lake City, Utah 84110-2550
Telephone: 801-532-1922

Date: November 20, 2003
ACT/bv

Enclosures: Form PTO-1449 or PTO/SB/08
Copy of documents cited

Document in ProLaw



PTO/SB/08B(10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 1

Complete if Known

Application Number	10/676,847
Filing Date	October 1, 2003
First Named Inventor	Veldhuis et al.
Group Art Unit	To be assigned
Examiner Name	To be assigned
Attorney Docket Number	2183-61391JS

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		LIU et al., Interferon-B administration confers a beneficial outcome in a rabbit model of thromboembolic cerebral ischemia, Neuroscience Letters, 2002, pp. 146-48, Vol. 327.	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.